AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06015035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab and anlotinib in combination with chemotherapy
Description: Neoadjuvant treatment involved administering anlotinib (10 mg orally, once a day, 2 weeks on and 1 week off) for anti-angiogenesis and sintilimab (200 mg) and chemotherapyfor three cycles. Surgical treatment was performed 4-6 weeks after the last chemotherapy cycle was completed. The primary endpoints assessed were pathological complete response (pCR) rate and safety.
Study NCT04873063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate
Description: BDP 3 mg bid (R product) BDP 6 mg qd (T product)
Study NCT04802655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video-game based exercise - Exergame
Description: Selected Kinect compatible video games from Microsoft Xbox one will be applied in this group. Four video games will be selected for a session (each game will last 10 mins). Video games are active video games which participants have to use their body parts in order to control games.
Study NCT04802655 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Activity Based Exercise Group (AG)
Description: Task-oriented exercises to be performed in standing and sitting positions, including upper extremity and trunk, will be applied to the activity-based exercise group in addition to routine NDT training. Examples for activities; stepping and putting stickers on the wall, treading the play dough placed on a step board within one leg stance; reach-grasp activities progressively from sitting to standing, throwing and catching balls on a balance board.
Study NCT06241482 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enhanced recovery after surgery
Description: The technologies, processes and measures of enhanced recovery after surgery focus on the following aspects:~1. Early assessment and treatment~2. Optimized anesthetic protocol~3. Reducing surgical stress~4. Multi-modal comprehensive monitoring~5. Comprehensive diagnosis and treatment in neurosurgical intensive care~6. Intensive early rehabilitation treatment
Study NCT06241482 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Conventional therapy in neurocritical care.
Study NCT06240143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: intradermal
Study NCT06240143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: intradermal
Study NCT06240143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: intravenous
Study NCT06739707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MD-18
Description: MD-18 administered subcutaneously to healthy individuals with overweight or obesity.
Study NCT04548947 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold snare polypectomy in conjunction with a submucosal injection
Description: The cold snare polypectomy in conjunction with a submucosal injection is a procedure during which the endoscopist resects the colorectal polyps during a colonoscopy, without any electrocautery.
Study NCT06740188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptamine balanced antidepressants trazodone
Description: The intervention group was given only 5-hydroxytryptamine balanced antidepressants trazodone
Study NCT06740188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram hydrobromide combined with zolpidem
Description: the control group was given citalopram hydrobromide combined with zolpidem
Study NCT06221644 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: [18F]SynVesT-1 PET/CT
Description: 60 MSA patients (30 MSA-P subtype and 30 MSA-C subtype) and 30 age-matched healthy controls (HCs) underwent \[18F\]SynVesT-1 PET/CT for synaptic density assessment
Study NCT06628115 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cerament V or G
Description: Cerament V or G implantation into forefoot or mid foot bone, and 7-10 days of oral antibiotics.
Study NCT05493735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hcl 2% Jelly
Description: Participants in the experimental arm will undergo pessary removal and reinsertion after the application of lidocaine topical gel.
Study NCT05493735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Jelly
Description: Participants in the control arm will undergo pessary removal and reinsertion after the application of lubricating jelly.
Study NCT04231006 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High dose rate brachytherapy
Description: High dose rate brachytherapy will be delivered to the site of recurrence within the prostate gland based on MRI and PSMA PET/CT
Study NCT06690333 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker
Description: Transvenous pacemaker with left bundle area pacing
Study NCT06690333 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker
Description: Transcatheter pacemaker with MICRA AV
Study NCT04862767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TASO-001((TGF-β2 targeting anti-sense oligonucleotide)
Description: 96 hour continuous infusion
Study NCT04862767 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: SC, Bid
Study NCT05651243 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone Ester Supplement
Description: Oral ingestion of a ketone supplement combined with a flavoring agent and diluted in water
Study NCT05651243 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral ingestion of cellulose combined with a flavoring agent and diluted in water
Study NCT05612204 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy under MRI
Description: Biopsy under MRI
Study NCT05219864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream
Description: Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
Study NCT05219864 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle cream is a topical formulation applied as a thin film to affected areas.
Study NCT05460520 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: VOR Readaptation
Description: The stimulus will be a combination of horizontal visual motion and a head maneuver. The subject will sit in a stationary chair, and a treatment provider will stand behind the subject. While the subject views the slow horizontal motion up to 10°/s of vertical stripes, the provider will gently hold the head of the subject above the ears and tilt the head in the roll (side-to-side) or pitch (up-down) plane by approximately ±20° at the frequency of 0.2 to 0.05 Hz for up to 10 min. The treatment will be repeated with breaks of approximately 5 min. A treatment session will last no longer 120 min including the breaks.~In Groups 1, 3, and 4, subjects will sit in a chair placed in the center of a cylindrical enclosure of a 95 cm radius, and full-field visual motion will be generated with light projected on the wall of this chamber. In Group 2, visual motion will be presented on the screen of a VR headset. Unlike groups 3 and 4, groups 1 and 2 do not receive any complementary treatment.
Study NCT05460520 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VOR Readaptation
Description: The stimulus will be a combination of horizontal visual motion and a head maneuver. The subject will sit in a stationary chair, and a treatment provider will stand behind the subject. While the subject views the slow horizontal motion up to 10°/s of vertical stripes, the provider will gently hold the head of the subject above the ears and tilt the head in the roll (side-to-side) or pitch (up-down) plane by approximately ±20° at the frequency of 0.2 to 0.05 Hz for up to 10 min. The treatment will be repeated with breaks of approximately 5 min. A treatment session will last no longer 120 min including the breaks.~In Groups 1, 3, and 4, subjects will sit in a chair placed in the center of a cylindrical enclosure of a 95 cm radius, and full-field visual motion will be generated with light projected on the wall of this chamber. In Group 2, visual motion will be presented on the screen of a VR headset. Unlike groups 3 and 4, groups 1 and 2 do not receive any complementary treatment.
Study NCT05460520 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: VOR Habituation
Description: The subject will sit in a chair placed in the center of a cylindrical enclosure of a 95 cm radius. Physical motion will be generated by rotating the chair sinusoidally to the left and right, and full-field visual motion will be generated with light projected on the wall of this chamber. Velocity storage will be weakened by inducing a conflict between physical and visual motions. Subjects will be first treated with a stimulus with a peak speed of 5°/s. The stimulus speed will be gradually increased from 5°/s on Day 1 to 40°/s on Day 5. In total, the subjects are expected to undergo 200-280 min of treatment over the five days, broken up into several 10-20 min sessions per day with a 10-min break in between. If signs or symptoms of motion sickness are reported by the subject (nausea, sweating), the session will be immediately paused. Treatment may be continued after a short rest if the discomfort is alleviated or on the following day.
Study NCT05460520 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VOR Habituation
Description: The subject will sit in a chair placed in the center of a cylindrical enclosure of a 95 cm radius. Physical motion will be generated by rotating the chair sinusoidally to the left and right, and full-field visual motion will be generated with light projected on the wall of this chamber. Velocity storage will be weakened by inducing a conflict between physical and visual motions. Subjects will be first treated with a stimulus with a peak speed of 5°/s. The stimulus speed will be gradually increased from 5°/s on Day 1 to 40°/s on Day 5. In total, the subjects are expected to undergo 200-280 min of treatment over the five days, broken up into several 10-20 min sessions per day with a 10-min break in between. If signs or symptoms of motion sickness are reported by the subject (nausea, sweating), the session will be immediately paused. Treatment may be continued after a short rest if the discomfort is alleviated or on the following day.
Study NCT05460520 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Visual Motion Desensitization
Description: The subject will be situated in darkness and view the movement of a visual pattern presented on a disk, sized 1 m in diameter and placed 1 m away from the subject with its center at the eye level. The disk will be rotated clockwise and counter-clockwise for up to 10 min at a fixed maximal speed within a treatment session but varying across sessions between 5 to 60°/s. Within a single session, the visual stimulus will be first presented with the subject sitting upright in a chair, and then the treatment will be repeated with the subject standing. The disk will be mounted on a vertical sled, so the center of rotation can be kept at the eye level when sitting and standing. A treatment session will be repeated or conducted with an increased visual motion speed up to 60°/s according to the subject's readiness. In total, the subjects are expected to undergo up to 300 min of treatment over the five days, broken up into several sessions per day with a 10-min break in between
Study NCT05460520 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Opposing visual motion stimulus
Description: The investigators characterize gravitational pull as a misaligned sense of upright in the velocity storage mechanism, and hypothesize that that this misalignment can be corrected with an opposing visual motion stimulus, e.g., backward pulling will be corrected with upward visual motion.~Patients in Group 5 will undergo view visual motion in a physical setting, and those in Group 6 under a VR setting. In total, the subjects are expected to undergo up to 300 min of treatment over the five days, broken up into several sessions of 1-10 min per day with an approximately 5-min break in between.
Study NCT05583162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Sport Project
Description: 2 interactive information lectures (given per class of 30 pupils), and 4 interactive workshops (given to sex-homogenous groups of 10 pupils). One per week, a total of 6 weeks with intervention.
Study NCT05244213 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg Q3W
Study NCT05244213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5, d1 every 3 weeks
Study NCT05244213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 260 mg/m2, d1 every 3 weeks
Study NCT05962307 — intervention group
Intervention type: DRUG
Intervention: Bulevirtide
Description: dose of 2 mg/day subcutaneously
Study NCT05795621 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IBI311
Description: 10 mg/kg on Day 1 followed by 20 mg/kg q3W for the remaining 7 infusions for phase II/III.
Study NCT05795621 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: IBI311
Description: 10 mg/kg on Day 1 followed by 20 mg/kg q3W for the remaining 7 infusions for phase II/III.
Study NCT05795621 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 4 does of placebo for phase II; 8 does of placebo for phase III.
Study NCT06627712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBRT+PD-1 Inhibitor + Chemotherapy
Description: Radiotherapy: 24Gy/3f, once every other day; Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle; Carboplatin AUC=5, IV, administered on day 1 of each cycle.~Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks
Study NCT06627712 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PD-1 Inhibitor + Chemotherapy
Description: Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle; Carboplatin AUC=5, IV, administered on day 1 of each cycle.~Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks
Study NCT06699134 — intervention group
Intervention type: DEVICE
Intervention: Total knee arthroplasty
Description: Primary total knee replacement using Hi-Fatigue G Bone Cement and a Zimmer Biomet implant
Study NCT06699134 — intervention group
Intervention type: DEVICE
Intervention: Total Hip arthroplasty
Description: Primary total hip replacement using Hi-Fatigue G Bone Cement and a Zimmer Biomet implant
Study NCT06733701 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR-based intervention (VRReliever Software V0.3.4 fromXRHealth)
Description: The participant will be able to select between four VR environments: beach, lake, forest, or mountain scenery. Each provides an immersive audio and visual environment designed to reduce anxiety and promote relaxation. Each scene is rendered in a high-resolution and life-like fashion which participants can experience in a full 360 degrees. Participants will wear the headset for the duration of the egg retrieval procedure which is approximately 15-20 minutes.
Study NCT06733701 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: VR headset without any scenery
Description: VR headset without any scenery
Study NCT06741813 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ASCT
Description: The chemotherapy-based preconditioning regimen was BeEAM, which consisted of bendamustine (120-180 mg·m-2·day-1，days -8 to -7), etoposide (200 mg·m-2·day-1，days -6 to -3), cytarabine (400 mg·m-2·day-1，days -6 to -3), and melphalan (140 mg·m-2·day-1，days -2).
Study NCT05301699 — intervention group
Intervention type: OTHER
Intervention: data analysis; validating the nomogram
Description: Not Applicable. Our study did not involve intervention
Study NCT06550453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pabolizumab+ bevacizumab and CapeOX (bevacizumab + oxaliplatin + capecitabine)
Description: Pabolizumab is an lgG4 subclass monoclonal antibody humanized against PD-l molecules thatblocks the immune escape mechanism of cancer cells by inhibiting the PD-l receptor oflymphocytes, thereby allowing the immune system to destroy them.~In the single-arm study, all enrolled patients received a combination of chemotherapy and immunotherapy, as outlined below:~Pembrolizumab:~Day 1：Pembrolizumab injection 200mg was administered once and repeated every 21 days, expected to last 2-4 cycles. Two vials (200 mg) of pembrolizumab injection should be diluted into 100-200 mL of saline, and the infusion time should be more than 30 minutes.~Chemotherapy (CapeOX regimen):~Day 2: Bevacizumab (7.5 mg/kg) + Oxaliplatin (135 mg/m2) + Capecitabine (1 g/m2, did, d1-d14). Treatment repeated every 3 weeks (q3w) until disease progression or intolerable toxicity.
Study NCT05249920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edaravone Dexborneol Concentrated Solution for injection
Description: Edaravone and Dexborneol Concentrated Solution for Injection, 15 ml (37.5 mg, containing edaravone 30 mg and dexborneol 7.5 mg) in 3 ampoule bottles, twice a day for 10 to 14 days.
Study NCT05249920 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Edaravone Dexborneol placebo
Description: Edaravone and Dexborneol placebo, 15 ml in 3 ampoule bottles, twice a day for 10 to 14 days.
Study NCT05027282 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLEAR + BRILLIANT TOUCH(R) 1440-nm and 1927-nm handpieces.
Description: CLEAR + BRILLIANT TOUCH(R) diode laser 1440-nm and 1927-nm Combination Wavelength Treatment.
Study NCT05505890 — intervention group
Intervention type: OTHER
Intervention: suprainguinal fascia iliaca block
Description: Suprainguinal fascia iliaca block will be performed after the end of surgery for postoperative analgesia.
Study NCT06579248 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoral Device
Description: Device that circulates cooled water through the oral cavity.
Study NCT06013085 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy
Description: 6 weeks cognitive behavioral therapy
Study NCT06088446 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supplementary anesthetic injections
Description: Supplementary anesthetic injections after failed primary nerve block
Study NCT06741813 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allo-HSCT
Description: Chemotherapy-based preconditioning regimen consisted of cytarabine 4 g·m-2·day-1 (days -9), busulfan (3.2 mg·kg-1·day-1 administered intravenously on days -8 to -6) (day 0 being the first day of donor cell infusion), cyclophosphamide (1.8 g·m-2·day-1, days -5 to -4), and semustine (250 mg.m-2, day -3). For the patients older than 55 years old or with HCT-CI score of 3 or more, cyclophosphamide can be decreased to 1.0 g·m-2·day-1, days -5 to -4, and added fludarabine (30mg·m-2·day-1, days -6 to -2). Rabbit antithymocyte globulin (thymoglobulin, 1.5 to 2.5 mg/kg, days -5 to -2; Sanofi, France) was administered to the HID and URD groups or MSD HSCT recipients who older than 40 years old (1.5 mg/kg, days -4 to -2).~All MSD, HID, and URD HSCT recipinets received cyclosporine A (CsA), mycophenolate mofetil (MMF), and short-term methotrexate (MTX) for GVHD prophylaxis. CsA (2.5 mg/kg, q12h, intravenous \[i.v.\]) was used from day -9, of which the trough concentration was adjusted to 150-250 ng
Study NCT06737913 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAI Adebrelimab
Description: Hepatic arterial infusion (HAI) of Adebrelimab (ADE) (1200mg, IA, Q3W)
Study NCT06329453 — intervention group
Intervention type: PROCEDURE
Intervention: Colon Tissue Biopsy
Description: Colonoscopy and colon tissue biopsy.
Study NCT06737913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous infusion (IV) of Adebrelimab (ADE)
Description: intravenous infusion (IV) of Adebrelimab (ADE) (1200mg, IV, Q3W)
Study NCT06737913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous infusion (IV) of Bevacizumab (Bev.)
Description: intravenous infusion (IV) of Bevacizumab (Bev.) (15mg/kg, IV, Q3W)
Study NCT06737913 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAIC with FOLFOX regimen
Description: HAIC with FOLFOX regimen (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil bolus 400 mg/m2 on day 1, and 5-fluorouracil infusion 2500 mg/m2 for 46 hours via hepatic artery Q4W)
Study NCT06737913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab and bevacizumab maintainance treatment
Description: The two arms continue the triple combination treatment up to 6 cycles and then received receive intravenous combination therapy of adebrelimab and bevacizumab for maintainance until disease progression or intolerable toxicity
Study NCT06742138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL2109
Description: QL2109 will be given 1800 mg subcutaneously at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects will receive pre-infusion medications before infusions to mitigate potential IRRs.
Study NCT06742138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: Intervention Description：Pomalidomide will be administered at full dose of 4 mg orally (PO) on Days 1 through 21 of each 28-day cycle
Study NCT06742138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Intervention Description：Pomalidomide will be administered at full dose of 4 mg orally (PO) on Days 1 through 21 of each 28-day cycle